ME Therapeutics Holdings, Inc. (TSE:METX) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
ME Therapeutics Holdings Inc. has announced a strategic partnership with NanoVation Therapeutics to develop mRNA-based cancer therapies targeting myeloid cells, utilizing NanoVation’s advanced lipid nanoparticle technologies. The collaboration will focus on testing the delivery and efficacy of these therapies in a preclinical mouse model, with the potential to fast-track new cancer treatments. This initiative combines ME Therapeutics’ expertise in immuno-oncology with NanoVation Therapeutics’ leading RNA delivery technology.
For further insights into TSE:METX stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
- Ford Stock (NYSE:F) Notches Up as Eddie Bauer Gets a Spiritual Successor in Filson
- “…Nearly Impossible to Get More…”: Intel Stock (NASDAQ:INTC) Surges as Intel Starts Selling High-End Chips to Laptop Makers
- “Get Out and See America,” Boeing Stock (NYSE:BA) Slides as Boeing Backs Sean Duffy Travel Show